尿液白蛋白与总蛋白检测的标准化挑战
本文讨论尿液白蛋白(UA)和总蛋白(UTP)检测缺乏跨厂商标准化的问题。2013年研究显示16种体外诊断医疗器械(IVD-MD)检测332份新鲜患者样本的UA均值差异达37%-45%,可能导致慢性肾脏病错误分类。UA标准化项目已开发高阶认证参考物质和参考测量程序,而UTP因技术限制尚无改进计划。
要点
- 不同厂商IVD-MD的UA检测结果差异可达37%-45%,可能影响CKD分类。
- UA标准化项目已建立高阶CRM和RMP,未来有望实现结果标准化。
- UTP检测结果差异约50%,因缺乏适用参考物质暂无标准化计划。
核心结论
- 当前UA和UTP检测缺乏跨IVD-MD的标准化,可能影响基于固定阈值的临床决策。
- UA标准化项目已开发高阶CRM和RMP,有望近期实现标准化。
- UTP因技术限制目前无改进结果一致性的计划。
研究设计与样本
- 本文为综述,引用2013年研究比较16种IVD-MD检测332份新鲜患者样本的UA结果。
主要发现
- 2013年研究中16种IVD-MD检测332份新鲜患者样本的UA均值差异为37%-45%。
- UA结果差异可能导致慢性肾脏病患者错误分类和医疗决策错误。
- UTP外部质量保证项目数据显示不同IVD-MD间差异约50%。
关键数值与推荐
- 现行临床实践指南推荐基于UA或UTP的固定阈值进行医疗决策。
- UA的IVD-MD校准方案缺乏适用的高阶认证参考物质或参考测量程序。
- UTP的IVD-MD使用不同化学反应,对尿中不同蛋白的测量响应不同且随疾病类型变化。
临床怎么用
- 临床解读UA和UTP结果时应考虑检测方法及厂商间差异对阈值判断的影响。
- 关注UA标准化进展,未来可能改善结果可比性。
- UTP结果解读需谨慎,因不同IVD-MD间差异可达约50%。
局限性
- UTP因技术限制目前无标准化计划,结果一致性难以改进。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Urine albumin (UA) and total protein (UTP) are commonly measured to assess kidney diseases. Current clinical practice guidelines recommend fixed threshold values for making medical decisions based on UA or UTP. However, neither biomarker has standardized results from in vitro diagnostic medical devices (IVD-MDs) from different manufacturers used by medical laboratories. In a 2013 study, 37%-45% differences in mean values for UA measurements of 332 freshly collected patient's samples were observed among 16 IVD-MDs. The differences in UA results among the IVD-MDs had the potential to cause erroneous classifications of chronic kidney disease patients and errors in medical decisions. Current IVD-MDs for UA use immunoassays that are highly selective for measuring the protein. However, calibration schemes for UA IVD-MDs do not have fit-for-purpose higher-order certified reference materials (CRMs) or reference measurement procedures (RMPs) available. A standardization program organized by the US National Institute of Diabetes and Digestive and Kidney Diseases and the International Federation of Clinical Chemistry and Laboratory Medicine has worked with collaborators to develop higher-order CRMs and RMPs suitable for use in standardizing calibration traceability of IVD-MDs for measuring UA. Transition to using the new reference system by IVD-MD manufacturers is expected to achieve standardized UA results in the near future. Data from external quality assurance programs for UTP show differences between different IVD-MDs on the order of 50%. IVD-MDs for UTP use several different chemical reactions that have different measurement responses for the different proteins found in urine which themselves vary with the type of disease. Consequently, there is not a coherent approach to developing a CRM or RMP that is suitable for use as a higher-order reference for standardized calibration of IVD-MDs for UTP. Due to these technical limitations, there is no currently planned activity to improve agreement of results for UTP measurements.
引用
- Miller WG, Seegmiller JC, Bachmann LM, et al. Measuring urine albumin and total protein. Nephrol Dial Transplant. 2026. PMID: 41854357. doi:10.1093/ndt/gfag060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。